Oncology Brothers: Practice-Changing Cancer Discussions

Join us for another insightful episode of the Oncology Brothers podcast as we dive into the latest breakthroughs in breast cancer research from the San Antonio Breast Cancer Symposium 2024. In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Sara Tolaney from Dana-Farber Cancer Institute to discuss three pivotal studies: 1.⁠ ⁠DESTINY-Breast06 - An update on the efficacy of T-DXd in HER2 low and ultra-low breast cancer patients, highlighting its potential to change treatment paradigms for endocrine refractory disease. 2.⁠ ⁠DESTINY-Breast12 - Exploring the robust intracranial activity of T-DXd in patients with brain metastases and its impact on quality of life. 3.⁠ ⁠PATINA Trial - A groundbreaking study on the use of CDK4-6 inhibitors in combination with trastuzumab and pertuzumab for ER-positive, HER2-positive breast cancer, showcasing impressive progression-free survival rates. Tune in as we unpack the implications of these studies for clinical practice and discuss the future of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates on oncology research and treatment strategies! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers For more information, visit our website: OncologyBrothers.com #OncologyBrothers #BreastCancer #SABCS2024 #TDXD #PATINA #CancerResearch #Podcast

Dr. Jame Abraham, a leading medical oncologist specializing in breast cancer at the Cleveland Clinic, shares groundbreaking insights from the SABCS 2024. He discusses the EUROPA trial, revealing the impact of treatment choices for patients over 70. The conversation dives into the TAILORx updates, highlighting anthracycline benefits for high-risk younger patients. Dr. Abraham also explores the PADMA study, affirming the role of CDK4/6 inhibitors, and the promising EMBER-3 results with new oral drugs for advanced cases. A must-listen for cancer treatment innovations!

In the third of this 4-part podcast series on hepatocellular carcinoma (HCC), the Oncology Brothers, Drs. Rahul and Dr Rohit Gosain, are joined by hepatologist Dr. Maria Reig and interventional radiologist Dr. Emil Cohen to explore treatment strategies for patients with intermediate-stage HCC. The experts share valuable insights into the available treatment options for this heterogeneous patient group and explore the role of systemic treatments and multimodal approaches in achieving optimal patient outcomes.   The conversation dives deep into real-world clinical challenges in managing patients with intermediate HCC, including treatment sequencing and strategies based on the experts' experience in clinical practice and the available data. The speakers also highlight variations in practice across different centres and geographic regions. Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

In this discussion, Dr. Laura Huppert, a medical oncologist from UCSF, highlights key trials from SABCS 2024. She explores the INSEMA study's potential reduction of axillary surgery for early-stage hormone receptor-positive breast cancer, which could enhance patient quality of life. The conversation shifts to KEYNOTE-522, revealing the latest on Pembrolizumab and promising biomarkers for triple-negative breast cancer. Lastly, the OlympiA study shows significant gains in survival for BRCA-positive patients with Olaparib. Expert insights and practical takeaways abound!

Dr. Robert Orlowski, an expert in multiple myeloma from MD Anderson Cancer Center, joins the discussion on groundbreaking ASH 2024 research. They explore the AQUILA study revealing early daratumumab intervention benefits, and a meta-analysis promoting quadruplet therapy as the new standard. The benefits of CAR-T therapy for lenalidomide-refractory patients are also highlighted. Furthermore, the use of IVIG alongside BCMA-targeted therapies shows promise in reducing infections and improving survival rates. Tune in for vital insights on the future of myeloma treatment!

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of Zanidatamab, a bispecific HER2 antibody, for HER2 amplified, unresectable, locally advanced, or metastatic biliary tract cancer. Join us as we discuss the HERIZON-BTC-01 study with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center and one of the study's authors. We explore the significance of HER2 testing in biliary tract cancers, the study's design, key findings, and the implications for treatment strategies in the community oncology setting. Key topics include: • Overview of biliary tract cancer and its treatment landscape • Study design and patient characteristics from the HERIZON-BTC-01 trial • Key findings, including overall response rates and duration of response • The importance of HER2 testing and its implications for treatment sequencing • Side effect profiles and management strategies for Zanidatamab • Future directions and ongoing clinical trials Don't miss this insightful discussion that highlights the exciting advancements in HER2-targeted therapies for biliary tract cancer. Make sure to subscribe for more updates on recent FDA approvals, treatment algorithms, and conference highlights. We look forward to seeing you at GI ASCO 2025 in person! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Welcome to the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. John Allan from New York Presbyterian Hospital to discuss the latest highlights from ASH 2024, focusing on Chronic Lymphocytic Leukemia (CLL). We dived into three key studies: 1.⁠ ⁠SEQUOIA Update: Discover how this study led to the approval of Zanubrutinib in the frontline setting and its impressive progression-free survival rates compared to traditional chemotherapy. 2.⁠ ⁠AMPLIFY Study: Learn about the exciting combination of Acalabrutinib with Venetoclax and Obinutuzumab, and how it may pave the way for the first oral doublet/triplet combination approval in the U.S. 3.⁠ ⁠Ongoing Trials: We touch on the CELESTIAL TN-CLL trial and the promising combination of Zanubrutinib with Sonrotoclax, a new BCL-2 inhibitor. Additionally, we discuss the evolving role of CAR-T therapy in CLL, especially for patients who have progressed through multiple lines of treatment. Join us for an insightful discussion on the future of CLL treatment options, the importance of balancing efficacy and side effects, and the exciting developments in the field. Don't forget to check out our other ASH and SABCS 2024 discussions! Subscribe to stay updated on the latest in oncology research and treatments! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Dr. Jason Westin, a lymphoma expert at MD Anderson, and Dr. Surbhi Sidana, who leads Stanford's Myeloma CAR-T program, dive into the intricacies of CAR-T cell therapy. They discuss its powerful mechanism and its application in treating cancers. The conversation highlights acute side effects like cytokine release syndrome and neurotoxicity, alongside strategies for their management. Chronic side effects, including infection risks and monitoring practices, are also explored, providing vital insights for oncologists on patient care.

Dr. Uma Borate, a leukemia treatment expert from The Ohio State University, joins the hosts for an insightful discussion on breakthroughs from ASH 2024. They delve into the promising KOMET 007 study on the Menin inhibitor Ziftomenib, noting its effectiveness for patients with specific genetic mutations. The conversation shifts to the comparison between CPX351 and traditional 7+3 induction therapies, revealing key insights about response rates. Additionally, they explore the role of Venetoclax in treating patients without actionable mutations, emphasizing NGS testing's vital role in targeted therapies.

In the second episode of a 4-part podcast series on HCC, the Oncology Brothers, Drs Rahul and Rohit Gosain, host a podcast discussion between Dr Lorenza Rimassa and Prof. Arndt Vogel on 2nd line treatment selection in advanced HCC and when to switch. The discussion covers a range of topics, including 2nd line options for advanced HCC after progression on 1st line TKIs and IO-based therapies, as well as: How to approach sequencing in clinical practice The available data supporting sequencing strategies When to switch to 2nd line therapy and what to consider when doing so This is the second video podcast episode in a 4-part series. Access the rest of the series here: Part 1 - The use of IO in unresectable HCC Part 3 - Intermediate HCC: treatment options and strategies (coming soon) Part 4 - The evolving role of IO in intermediate HCC (coming soon)   Clinical takeaways Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life. Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation.   Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!   Website: http://www.oncbrothers.com/   X/Twitter: https://twitter.com/oncbrothers   Contact us at info@oncbrothers.com